~~<i id='51AF1C5A41'><strike id='51AF1C5A41'><tt id='51AF1C5A41'><pre id='51AF1C5A41'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：Wikipedia 2025-10-02 09:39:39 Page View：36958

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： CVS is willing to dump 10% of its Medicare Advantage members
Next article： After affirmative action ruling, medical educators look to 'holistic review'

comprehensive

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

Christmas in the PICU brings some surprising joy

Calsmilesonher8thbirthday,justbeforeChristmas,afterbeingextubated.CourtesyMariaKefalasInthedaysleadi

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Grail spinoff by Illumina should end disastrous merger attempt

AdobeIllumina,theleadingmakerofDNAsequencingmachines,saidSundaythatitwoulddivestGrail,thedeveloperof

WSS

fashion

fashion

knowledge

comprehensive

Grail spinoff by Illumina should end disastrous merger attempt